Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab for High-Risk Pre-malignant Upper Aerodigestive Lesions
NCT00524017Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2007
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of KL-140 in precancerous condition, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started May 2007; status: completed.
02
Drugs
KL-140
03
Conditions
precancerous condition
Beyond the preview
Go deeper on NCT00524017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00524017.